NAM
RPRX icon

Nissay Asset Management’s Royalty Pharma RPRX Stock Holding History

Nissay Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
+56,729
New +$2.95M 0.01% 445
2025
Q3 		– Sell
-48,506
Closed -$1.75M – 699
2025
Q2 		$1.75M Sell
48,506
-171
-0.4% -$5.67K 0.01% 539
2025
Q1 		$1.52M Buy
48,677
+196
+0.4% +$6.21K 0.01% 563
2024
Q4 		$1.24M Buy
48,481
+349
+0.7% +$9.25K 0.01% 608
2024
Q3 		$1.36M Buy
48,132
+2,031
+4% +$56.3K 0.01% 602
2024
Q2 		$1.22M Buy
46,101
+1,738
+4% +$48.2K 0.01% 602
2024
Q1 		$1.35M Buy
44,363
+604
+1% +$17.8K 0.01% 586
2023
Q4 		$1.23M Buy
43,759
+2,693
+7% +$74K 0.01% 582
2023
Q3 		$1.11M Buy
41,066
+1,871
+5% +$55.6K 0.01% 587
2023
Q2 		$1.2M Buy
39,195
+2,235
+6% +$75.7K 0.01% 565
2023
Q1 		$1.33M Sell
36,960
-1,254
-3% -$46.5K 0.01% 531
2022
Q4 		$1.51M Sell
38,214
-321
-0.8% -$13.4K 0.01% 497
2022
Q3 		$1.55M Buy
38,535
+1,708
+5% +$73K 0.02% 474
2022
Q2 		$1.55M Buy
36,827
+89
+0.2% +$3.65K 0.02% 482
2022
Q1 		$1.43M Buy
36,738
+1,023
+3% +$40.2K 0.01% 549
2021
Q4 		$1.42M Buy
35,715
+16,761
+88% +$651K 0.01% 567
2021
Q3 		$685K Buy
18,954
+824
+5% +$32K 0.01% 675
2021
Q2 		$743K Buy
18,130
+201
+1% +$8.55K 0.01% 678
2021
Q1 		$782K Buy
17,929
+5,056
+39% +$240K 0.01% 652
2020
Q4 		$644K Buy
+12,873
New +$546K 0.01% 649

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nissay Asset Management's RPRX Position: Q2 2026 in Review

Nissay Asset Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 56,729 shares worth $3.18M. The stake represents 0.01% of the portfolio and ranks #445 among its holdings. This is a return to the name: Nissay Asset Management previously reported a position in RPRX as recently as Q2 2025.

Nissay Asset Management first reported a position in RPRX in Q4 2020 and has held it in 20 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Nissay Asset Management held 56,729 shares of Royalty Pharma worth $3.18M as of Q2 2026.
  • Royalty Pharma was a new Nissay Asset Management position in Q2 2026.
  • Royalty Pharma made up 0.01% of Nissay Asset Management's portfolio in Q2 2026, its #445 holding.
  • Nissay Asset Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 20 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.